[Endothelin-1 and arteriosclerosis].
Sugiyama
Toru
T
Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School.
Hirata
Yukio
Y
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D002455:Cell Division; D003619:Dansyl Compounds / Q000627:therapeutic use; D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D019332:Endothelin-1 / Q000502:physiology*; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000473:pathology; D009389:Neovascularization, Pathologic; D010456:Peptides, Cyclic / Q000627:therapeutic use; D044022:Receptor, Endothelin A / Q000502:physiology; D044023:Receptor, Endothelin B / Q000502:physiology; D014661:Vasoconstriction
D003619:Dansyl Compounds; D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D019332:Endothelin-1; D010456:Peptides, Cyclic; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; C085754:5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide; C088196:TAK 044; C072247:cyclo(Trp-Asp-Pro-Val-Leu)